WallStSmart

EMCOR Group Inc (EME)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

EMCOR Group Inc generates 6755% more annual revenue ($17.75B vs $258.90M). EME leads profitability with a 7.5% profit margin vs -15.5%. EME earns a higher WallStSmart Score of 64/100 (C+).

EME

Buy

64

out of 100

Grade: C+

Growth: 8.7Profit: 7.0Value: 5.0Quality: 6.3
Piotroski: 5/9Altman Z: 4.41

ZEPP

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EME.

ZEPPUndervalued (+48.9%)

Margin of Safety

+48.9%

Fair Value

$46.96

Current Price

$18.01

$28.95 discount

UndervaluedFair: $46.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EME4 strengths · Avg: 9.0/10
Return on EquityProfitability
39.2%10/10

Every $100 of equity generates 39 in profit

Altman Z-ScoreHealth
4.4110/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
19.7%8/10

19.7% revenue growth

EPS GrowthGrowth
30.0%8/10

Earnings expanding 30.0% YoY

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

EME4 concerns · Avg: 3.3/10
P/E RatioValuation
30.4x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.4x4/10

Trading at 11.4x book value

Profit MarginProfitability
7.5%3/10

7.5% margin — thin

Free Cash FlowQuality
$-28.15M2/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.3/10
Market CapQuality
$270.28M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Free Cash FlowQuality
$-26.48M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : EME

The strongest argument for EME centers on Return on Equity, Altman Z-Score, Revenue Growth. Revenue growth of 19.7% demonstrates continued momentum. PEG of 1.08 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : EME

The primary concerns for EME are P/E Ratio, Price/Book, Profit Margin.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

EME profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

ZEPP generates stronger free cash flow (-26M), providing more financial flexibility.

Bottom Line

EME scores higher overall (64/100 vs 38/100) and 19.7% revenue growth. ZEPP offers better value entry with a 48.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EMCOR Group Inc

INDUSTRIALS · ENGINEERING & CONSTRUCTION · USA

EMCOR Group, Inc. provides electrical and mechanical installation and construction services in the United States. The company is headquartered in Norwalk, Connecticut.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?